Pick­ing up the pieces left from an Alzheimer’s im­plo­sion, Ax­o­vant is start­ing over by div­ing in­to gene ther­a­py

Af­ter get­ting blast­ed by the fail­ure of its lead drug for Alzheimer’s, Vivek Ra­maswamy’s Ax­o­vant $AX­ON is go­ing to try and blaze a new path …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

Director of IT, Security

Viridian Therapeutics

Waltham, MA, USA